Orange Investment Advisors Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Orange Investment Advisors Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.7% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,402 shares of the medical research company’s stock after selling 2,231 shares during the quarter. Thermo Fisher Scientific makes up about 1.0% of Orange Investment Advisors Inc.’s holdings, making the stock its 26th biggest position. Orange Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $7,570,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. High Note Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $28,000. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $29,000. Finally, Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $605.09.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $513.54 on Monday. The firm has a fifty day moving average of $474.08 and a two-hundred day moving average of $519.85. The firm has a market cap of $190.84 billion, a P/E ratio of 28.23, a P/E/G ratio of 2.27 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $401.45 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the company posted $5.15 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.